Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 4, Issue 3, 2023

Effect of Teriparatide and Bisphosphonates in Advanced Patients with Osteoporosis

Download as PDF

DOI: 10.23977/medsc.2023.040317 | Downloads: 7 | Views: 330

Author(s)

Panxiang Li 1, Lan Yang 1, Shike Wu 1, Xiaoming Wu 1, Yilei Liu 1, Meng Cao 2

Affiliation(s)

1 Bone Three Families, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China
2 Science and Education, Baoding No.1 Central Hospital, Baoding, Hebei, 071000, China

Corresponding Author

Lan Yang

ABSTRACT

This paper mainly analyzes and studies the clinical treatment effect of teriparatide and bisphosphonates in elderly patients with osteoporosis.60 elderly osteoporosis patients admitted to our hospital from October 2021 to October 2022 were randomly selected and divided into two groups: observation group and control group by single and single coin method, and the number of patients in each group was 30.30 patients in the control group were treated with zoledronic acid for advanced osteoporosis, and 30 patients in the observation group were treated with teriparatide and bisphosphonate. Comparing the pain scores, bone density values, bone metabolism indicators and the incidence of adverse reactions between the two groups. Among them, the VAS score (1.22 ± 0.17) was lower than that of the control group (3.69 ± 1.30), (p <0.05); the observation group and the control group (p <0.05); the levels of calcium, blood phosphorus, osteocalcin and alkaline phosphatase increased after treatment, and the observation group, (p <0.05); there was no difference in adverse reactions between the observation group and the control group, (p> 0.05). The results show that for patients with osteoporosis, using teriparatide and bisphosphate sequential treatment, can effectively relieve the pain symptoms, and improve the bone mineral density, improve the bone metabolism index of patients, reduce the incidence of adverse reactions, ensure the safety and effectiveness of medication, can promote the application value in clinical high of a treatment.

KEYWORDS

Teriparatide; bisphosphonates; sequential treatment; osteoporosis in the elderly; clinical efficacy

CITE THIS PAPER

Panxiang Li, Lan Yang, Shike Wu, Xiaoming Wu, Yilei Liu, Meng Cao, Effect of Teriparatide and Bisphosphonates in Advanced Patients with Osteoporosis. MEDS Clinical Medicine (2023) Vol. 4: 126-130. DOI: http://dx.doi.org/10.23977/medsc.2023.040317.

REFERENCES

[1] Bao Huhe, Sun Guanwen, Wang Jian, et al. Observation of the efficacy of teriparatide and bisphosphonates in the sequential treatment of elderly osteoporosis patients [J]. Journal of Practical Clinical Medicine, 2021, 25 (16): 95-98.
[2] Lu Qiuju, Pu Qianghong. Meta-analysis of the efficacy and safety of teriparatide and bisphosphonates in treating glucocorticoid-induced osteoporosis [J]. Clinical medical practice, 2022, 31 (3): 166-169.
[3] Gu Yingying, Dong Wei. Progress in teriparatide treatment for osteoporosis [J]. Medical Herald, 2022, 41(9): 1331-1334.
[4] Wang Dongdong, Yu Xiaohua, Liu Fang. Effect of strontium ranelate combined with teriparatide in the treatment of primary osteoporosis and its effect on bone metabolism in elderly patients [J]. Zhongnan Journal of Medical Science, 2021, 49 (1): 81-84, 94.
[5] Yu Bing, Ding Xiurong, Zhang Yong. Clinical study of the parathyroid hormone agonist teriparatide in glucocorticoid-induced osteoporosis [J]. Practical drugs and clinical, 2021, 24 (11): 999-1002.
[6] Lou Xiaojun, Bian Pingda, Shou Zhangxuan, et al. Effect of continuous duration of teriparatide on efficacy in elderly female patients with osteoporosis [J]. Chinese Medicine, 2022, 17 (2): 241-243.
[7] Du Yanping, Cheng Qun. Mechanisms and strategies for the sequential treatment of osteoporosis using parathyroid hormone analogues and bisphosphonates [J]. Diagnostics Theory and Practice, 2020, 19 (3): 219-224.
[8] Yu Long, Wang Liang. Status and progress of osteoporosis in the elderly [J]. Chinese Journal of Clinical Health Care, 2022, 25 (1): 6-11.
[9] Chen Jiong. Comparison of the effects of three anti-osteoporosis drug treatments on recurrent fractures after PKP [J]. Journal of Clinical Rational Drug Use, 2022, 15 (19): 75-78.
[10] Hu Yi'an, Hong Haowei, Pan Jie, et al. Reticular Meta-analysis of anti-osteoporosis drugs for glucocorticoid - induced osteoporosis [J]. Prescription drugs in China, 2022, 20 (3): 76-80.
[11] Hu Zhonghui, Zhang Qian, Li Mei. Progress in biological targeted drug therapy for glucocorticoid-induced osteoporosis [J]. General Practice in China, 2022, 25 (6): 756-759.
[12] Lin Canbin. Clinical efficacy of different types of bisphosphonate drugs for osteoporosis [J]. Journal of Clinical Rational Drug Use, 2021, 14 (32): 109-111.
[13] Shao Wei. Analysis of the effectiveness of bisphosphonates plus alfacalcidol in treating patients with osteoporosis [J]. Capital Food and Medicine, 2021, 28 (10): 71-72.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4304
Visits: 190862

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.